UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

February 21, 2023
Date of Report (date of earliest event reported)

Asensus Surgical, Inc.

(Exact name of Registrant as specified in its charter)

Delaware	**0-19437**	**11-2962080**
(State or other jurisdiction of incorporation or organization)	**(Commission File Number)**	**(I.R.S. Employer Identification Number)**

1 TW Alexander Drive, Suite 160
Durham, NC 27703
(Address of principal executive offices)
919-765-8400
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock $0.001 par value per share	**ASXC**	**NYSE American**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On February 21, 2023, Asensus Surgical, Inc. (the "Company") is hosting an Investor Day to provide a corporate update to investors. The Company notified investors of the date of the Investor Day via press release issued on January 30, 2023. The information provided during such Investor Date is furnished as Exhibit 99.1 to this Form 8-K.

The information in this Item 7.01 and the Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

The Company issued a press release just prior to hosting its Investor Day on February 21, 2023. The press release is attached as Exhibit 99.2 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

Exhibit No.	Description
99.1	Corporate Presentation of Asensus Surgical, Inc. February 21, 2023
99.2	Press Release of Asensus Surgical, Inc., dated February 21, 2023
104	Cover Page Interactive Data File (formatted in inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ASENSUS SURGICAL, INC.

Date: February 21, 2023

/s/ Shameze Rampertab
Shameze Rampertab
Executive Vice President and Chief Financial Officer


ASENSUS
SURGICAL
Surgery
Reimagined
Performance-Guided Surgery – next
level technology that completely
changes the idea of what's possible.


Hotstart Video

02.21.23

Surgery Reimagined

Investor Day February 2023

SENSUS SURGICAL

PRESIDENT & CHIEF EXECUTIVE OFFICER

Anthony Fernando

ASENSUS SURGICAL

Forward-Looking Statements Disclosure

This presentation includes statements relating to the LUNA™ Surgical System next-generation program under development and an update on Asensus' strategic plan. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether we can successfully advance our Performance-Guided Surgery™ initiative, the risks and uncertainties related to our ability to successfully advance our LUNA System program through development, testing and regulatory approval on the timeline provided, or at all, the risk that we will not be able to successfully enter into definitive agreements with our collaborators, that the pace of adoption of our products by surgeons will increase, the success and market opportunity of our products, including the ISU and LUNA System, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the risks and uncertainties associated with the Company's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Agenda

- Welcome and overview
  Anthony Fernando, President & Chief Executive Officer
- Surgical robotics market
  Ethan Loiselle, Vice President, Global Marketing
- Performance-Guided Surgery – Building the future of surgery
  Next Generation Digital Surgery Platform – Dustin Vaughan, Vice President, R&D, Robotics
  KARL STORZ Partnership – Stephan Abele, Managing Director, KARL STORZ Venture ONE
  Intra-operative Clinical Guidance – Motti Frimer, Vice President, R&D, Digital Solutions
  Asensus Cloud – Brian Stellmach, Vice President, Digital Solutions
- Roadmap & Milestones
  Anthony Fernando, President & Chief Executive Officer
- Surgeon panel
  Dr. Amit Trivedi, Dr. Bernhard Kramer
  Moderator: Dr. Ed Chekan, Vice President, Medical Affairs & Professional Education
- Q&A
- Product demo and reception

The WHAT

AT

ASENSUS SURGICAL

WE BELIEVE

Digitizing the interface between surgeon and patient enables Performance-Guided Surgery to consistently deliver superior outcomes and a new standard of care.

WE UNDERSTAND

Hospitals and surgeons are under intense pressure to drive consistently excellent outcomes while optimizing resources.

WE DESIGN

Solutions and technology platforms to enhance surgeon capabilities, improve the surgical experience, and support hospital systems with innovative healthcare strategies.

The HOW

- ONE Global Team
- Innovate with Passion
- Focused Execution
- Drive High Engagement


How We Got Here Video

Who We Are

Akihisa Akao
General Manager, Japan

Dr. Ed Chekan
VP, Medical Affairs & Professional Education

Wouter Donders
VP & GM, Europe

Motti Frimer
VP, R&D, Digital Solutions

Kathleen Frost
VP, Intellectual Property

Ravi Kommineni
Head of Global Quality & Regulatory

Ethan Loiselle
VP, Global Marketing

Wesley Long
VP, Customer Excellence

Ken Nicolosi
Director, US Sales & Clinical Operations

Daniel Odermatt
VP, Upstream Marketing

Amanda Owens
VP, People

Daniel Potts
VP, Asia Pacific

Shameze Rampertab
Executive VP & Chief Financial Officer

Brian Stellmach
VP, Digital Solutions

Nicholas Summitt
Senior Director, Strategy & Development

Johan van Doremalen
VP, Europe Sales

Dustin Vaughan
VP, R&D, Robotics

Joshua Weingard
Chief Legal Officer

ASENSUS SURGICAL

We Are Pioneering the Future of Surgery

10,000+
Procedures

100+
Surgeons

2,300+
Patient Registry

300+
Patents[1]

Global
Regulatory Approvals

80+
Publications

1. Includes, globally issued plus pending applications


Surgeon Video

VICE PRESIDENT, GLOBAL MARKETING

Ethan Loiselle



The State of Surgery

- Minimally Invasive Surgery (MIS) is the gold standard, **yet penetration is less than 50% and outcomes continue to vary**[1,2]
- Robotics as an enabling technology **remain under penetrated globally** (~6%) despite two decades of developments

1. Oaks, et al. Society of Gynecologic Surgeons Systematic Review Group. Systematic review of robotic surgery in gynecology: robotic techniques compared with laparoscopy and laparotomy. J Minim Invasive Gynecol. 2011 May-Jun;18(3):351-65.
2. Moretti, et al. Surgical Results and Complications for Open, Laparoscopic, and Robot-assisted Radical Prostatectomy: A Reverse Systematic Review. Eur Urol Open Sci. 2022 Sep 8;44:150-161.

Next Level Thinking for Next Level Outcomes

Digital Surgery

Improving outcomes by reducing **variability**

Digital tools to increase safety, predictability & consistency

Minimally Invasive Surgery

Improving outcomes by reducing **invasiveness**

Vision systems & mechanical tools for intracorporeal dexterity

Open Surgery



ASENSUS SURGICAL

MIS: The Gold Standard

- 44% WW soft tissue procedures are performed laparoscopically[1]
- **Laparoscopy is better…**
  - Shorter length of stay
  - Reduced pain
  - Better outcomes
- **…but makes up less than 1/2 of procedures**
  - Increased complexity
  - Reduced access



Soft Tissue Surgical Procedures (2022)

LAP

ASENSUS SURGICAL

1. Datwyler / DHS Laparoscopic Devices Market Insight Dec 2021 combined with internal assessment of addressable procedures

Robotics Incremental Change

- Robotic Surgery today is ~6% of market[1]
- Incremental improvement vs. traditional laparoscopy
- Current Robotics adds challenges:
  - Higher learning curve
  - Cost per procedure
  - Surgeon disconnected from the OR
- Traditional Robotics has had little impact on patient outcomes vs. Laparoscopy



Soft Tissue Surgical Procedures (2022)

LAP

Robot

1. Deloitte / DHS Laparoscopic Devices Market Insight Dec 2021 combined with internal assessment of addressable procedures

Variability Can Be Reduced

Expanding clinical insights in real-time informs decision making to reduce surgical variability

Surgical Variability Impact Patients

- **1 in 5** surgical procedures result in a complication that impacts the patient.[1]
- The **volume of surgeries performed** can have a direct correlation to patient outcomes.[2,3]
- **Complication rates** vary by procedure and surgeon, leading to unpredictable financial burdens for hospitals.[4,5]

ASENSUS SURGICAL

1.Birkmeyer, et al. Surgical skill and complication rates after bariatric surgery. N Engl J Med. 2013;369(15):1434-1442
2.Markar, et al. Volume-outcome relationship in surgery for esophageal malignancy: 2000-2021. J Gastrointest Surg. 2023 May;26(5):1055-66.
3.Hendricks, et al. Systematic review and meta-analysis on volume-outcome. Int J Surg. 2021 Feb;86:24-31.
4.Lee, et al. Clinical and economic burden of colorectal and bariatric anastomotic leaks. Surg Endosc. 2020 Oct;34(10):4374-4381. doi: 10.1007/s00464-019-07210-1. Epub 2019 Nov 12.
5.La Regina, et al. Financial Impact of Anastomotic Leakage in Colorectal Surgery. J Gastrointest Surg. 2019 Mar;23(3):540-546. doi: 10.1007/s11605-018-3954-z. Epub 2018 Sep 13.

 |

What We've Learned

Listening to surgeons and surgical staff 10+ years.

Observing challenges in the OR through 10+ thousand procedures.

Gaining a global perspective across 10+ geographies.

- There is a need for tools that inform surgical decisions and enhance cognitive abilities in the OR.
- Surgical technology should promote collaboration, productivity and career longevity.
- Robotic Surgery platforms must become far more accessible, i.e. easier to obtain, use and learn.
- Operational cost barriers can be addressed to make Robotics broadly available.

ASENSUS SURGICAL

There are Missing Pieces in the OR

Patients

- Predictable outcome
- Fast recovery, with less pain
- Rapid return to normal activity

Surgeons

- Complete less invasive instruments
- Robotic precision and control
- Real-time decision support tools
- Connection to OR
- Productive and fulfilling career

OR Staff

- Easy setup / stay on schedule
- Simple instrument exchange
- Full patient access
- Interactive communication
- Standardization to familiar tools and supplies

Hospital

- Lower cost per procedure
- Reduced complications
- Performance metrics and dashboards
- Standardization

ASENSUS SURGICAL

The Next Evolution of Surgery


Then
Now
Future
21

Digitizing Surgery

Moving from an Analog to a Digital World

Robotics + Digital Interface + Machine Vision & Augmented Intelligence

Best in Class Robotics
PHYSICAL ADVANTAGE

- System versatility & footprint
- Full suite of surgical tools & partners
- Smallest 5mm wristed Instruments

Surgical Assistance
COGNITIVE ADVANTAGE

- Surgeon-driven and autonomous visualization
- Haptic feedback to "feel" the surgery

Clinical Intelligence
INFO TO SUPPORT SURGICAL DECISIONS

- Structural identification & no-fly zones
- Intra-operative guidance
- Procedural steps based on past surgeries
- Training and education of surgeons

ASENSUS SURGICAL

Performance-Guided Surgery

Clinical Intelligence and Real-Time Decision Support Tools That Drive Consistently Superior Outcomes



ASENSUS SURGICAL

Meet LUNA™

The Next Generation of Digital Surgery


LUNA Sizzle Video

VICE PRESIDENT, R&D, ROBOTICS

Dustin Vaughan

ASENSUS SURGICAL

LUNA System Overview

Instinctive
Surgeon Console

Collaborative
Robotic Manipulator Arms

Enabling
Instruments

ASENSUS SURGICAL

Building LUNA



- Senhance experience
- System architecture
- Leveraging global relationships
- Design for Excellence
- Regulatory mentality

Surgeon Console

Market leading 4K-3D visualization from KARL STORZ

(No 3D glasses required)

Accessible touch screen user interface

Unconstrained surgeon controls for seamless operation of robotic arms

ASENSUS SURGICAL

Manipulator Arm

Greater range of motion for improved surgical dexterity

Haptic feedback and virtual fulcrum for tissue protection

Capable drive system and rapid instrument exchange

Real-time guidance for ease of pre-operative setup

Reduced footprint for greater bedside maneuverability and patient access

ASENSUS SURGICAL

Instruments

- TrueWrist™ fully articulated 5mm instruments line
- Passive, Monopolar and Bipolar offerings
- Reusable
- Standard minimally invasive 3mm and 5mm trocars
- Continued development and manufacturing by KARL STORZ



ASENSUS SURGICAL


SENSUS
SURGICAL
LUNA
LUNA
LUNA
LUNA™
The Next Generation of Digital Surgery

KARL STORZ Collaboration

- Industry-leading imaging solutions
- Next-generation instrumentation
- Commercial scale

Managing Director, KARL STORZ VENTURE ONE

Stephan Abele

ASENSUS SURGICAL


STORZ
KARL STORZ—ENDOSKOPE
35

Facts and figures at a glance

Foundation	Fields	Business areas	Production sites
1945 in Tuttlingen (Germany)	Medical Technology	Human & Veterinary Medicine	Germany, USA, Estonia, Switzerland

8,300 Employees worldwide

1.97 billion Euro turnover in 2021

70 subsidiaries in 40 countries

STORZ KARL STORZ — ENDOSKOPE

The world is our home

STORZ
KARL STORZ — ENDOSKOPE

Hospitals worldwide value technologies from KARL STORZ

Leading Hospitals and healthcare partners worldwide rely on our innovations.

High-end operating rooms from KARL STORZ

OR1™ – Integrated operating room

- Integration of the OR into the hospital IT infrastructure
- Central control of the integration system for medical equipment and room functions

SCENARA® – The modular software platform

- Modular, expandable and cybersafe application platform
- Supports pre-, intra-, and postoperative processes
- Expanded documentation chain thanks to simple and safe access to endoscopic videos – at any time and any place — also on mobile devices

Optimal imaging makes the difference in robotic surgery

- Surgeons around the globe have relied on KARL STORZ imaging in their daily practice for decades.
- The 3D-4K video endoscope TIPCAM®1 Rubina™ fits perfectly for robotic surgery
- Robotic surgery benefits from outstanding image quality and excellent depth perception.
- NIR/ICG enables visualization of anatomical structures beyond what the human eye can see

KARL STORZ
ventureONE

STORZ
KARL STORZ—ENDOSKOPE

Performance-Guided Surgery

Clinical Intelligence and Real-Time Decision Support Tools That Drive Consistently Superior Outcomes



ASENSUS SURGICAL

VICE PRESIDENT, R&D, DIGIAL SOLUTIONS

Motti Frimer

Some Definitions

Artificial Intelligence

The ability of machines to do things that usually require human cognition, such as learning, problem-solving and decision-making.

Augmented Intelligence

The use of technology to enhance human intelligence, rather than replacing it.

Intraoperative Clinical Intelligence

The Asensus Intelligent Surgical Unit™ (ISU™)

ASENSUS SURGICAL

 |

Camera Control and Manipulation



Digital Tags



3D Digital Measurement





Evolution of the ISU

- Analytical Tools
- Safety Tools
- Training Tools

Analytical Tools Example

3D Measurement





Gastric Sleeve Procedure

Some features are still in development and the safety or effectiveness of these features have not been established.

Safety Tool Example

Establish 'No-Fly' Zones

ASENSUS SURGICAL

Some features are still in development and the safety or effectiveness of these features have not been established.

Training Tool Example

Real-time telestration

Some features are still in development and the safety or effectiveness of these features have not been established.

Performance-Guided Surgery

Clinical Intelligence and Real-Time Decision Support Tools That Drive Consistently Superior Outcomes



ASENSUS SURGICAL

Capture | Process | Deploy



VICE PRESIDENT, DIGIAL SOLUTIONS

Brian Stellmach

ASENSUS SURGICAL

Data & the Asensus Cloud

Data in the Past

- Nearly zero

Present

- Infrequent
- Unstructured

Future

- Massive
- Actively collected
- High quality
- Well-organized

ASENSUS SURGICAL

Customized Cloud Solution for Surgical Applications

Unique Considerations

- Huge video files (4K-3D)
- Privacy & security
- Adaptive scalability in storage, compute, etc.

ASENSUS SURGICAL

Data Automation Enhances Cloud Capabilities

- Democratization of Surgical Data Annotation
- Big Data Enrichment
- Future 3rd Party Integrations

ASENSUS SURGICAL

Data to Insights

Analytics Applications

Intra-operative

- Augmented Intelligence

Pre & Post Op

- Evaluating performance
- Comparative planning
- Workflow optimization
- Training, research, etc.

Cloud Partnerships

Google Cloud

Surgery Reimagined

Patients

Surgeons

OR Team

Hospital

Performance-Guided Surgery

ASENSUS SURGICAL

Key Milestones



1. Timelines to be finalizes as part of definitive agreement

Key Takeaways

- Surgical outcomes can be improved.
- Performance-Guided Surgery is surgery reimagined.
- Asensus is the right company to advance this vision.
- LUNA: Next-generation digital surgery platform and instruments.
- Standalone ISU: Incremental revenue stream.
- Digital surgery is more than just a robot.
- Clear pathway to execute and achieve our vision.

Surgeon Panel

The Next Evolution of Surgery

SURGEON

Dr. Amit Trivedi

Chair, Department of Surgery
Pascack Valley Medical Center, New Jersey (US)

SURGEON

Prof. Bernhard Krämer

Deputy Medical Director of Gynecology
Tuebingen University Hospital, Tuebingen (Germany)

MODERATOR

Dr. Ed Chekan

VP, Medical Affairs & Professional Education
Asensus Surgical

SENSUS SURGICAL

ON BEHALF OF OUR ENTIRE TEAM,

Thank You

Exhibit 99.2

Asensus Surgical Provides Corporate Update

RESEARCH TRIANGLE PARK, N.C.--(GLOBE NEWSWIRE)--February 21, 2023-- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, is providing this corporate update in conjunction with its previously announced Investor Day, which will be hosted today, beginning at 11:30am EST.

“Our vision is to revolutionize the way surgery is performed and ultimately the way patients are treated. To date, we have made tremendous progress evolving robotically-assisted surgery into Digital Laparoscopy with the combination of our Senhance® Surgical System and the intelligent capabilities of our Intelligent Surgical Unit™(ISU™). However, we expect more from a surgical solution,” said Anthony Fernando, President and Chief Executive Officer of Asensus. “We have first hand knowledge, shaped by thousands of real-world procedures and years of interactions with surgeons and hospitals, of what the market needs, which is much more than just a robot. The best solution will materially reduce surgical variability and deliver improved outcomes. We are working to deliver that solution, a new era of surgery called Performance-Guided Surgery, the foundation of which will be our new LUNA™ Surgical System and the clinical intelligence capabilities provided to surgeons through the ongoing development of the ISU.”

Based on its clinical and commercial experience to date, the Company is introducing an integrated Digital Surgery solution comprising a next generation surgical platform and instruments, real-time intraoperative clinical intelligence and a secure cloud platform to apply machine learning to deliver clinical insights. This Digital Surgery solution will enable the Company’s vision of Performance-Guided Surgery.

LUNA, the Company’s Next Generation Digital Surgery Platform

Designed based on the feedback received from over 10,000 digital laparoscopic procedures performed with the Senhance System, the LUNA Surgical System is the Company’s next generation digital surgery platform. Through a combination of advanced minimally invasive instrumentation, the first ever digital interface between the surgeon and the console, and industry-leading clinical intelligence tools, we believe LUNA is poised to revolutionize the way surgery is performed.

The LUNA Surgical System is under development, and not currently available for use.

The LUNA Surgical System is Asensus' next generation digital surgery platform that is poised to revolutionize the way surgery is performed.

New Intelligent Surgical Unit Capabilities Announced

The Company's digital surgical platforms are powered by the ISU. The ISU enables real-time surgical image analytics coupled with machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field. It allows the surgeon to measure anatomy, place digital tags, enhance the surgical image and offers Augmented Intelligence (AI) driven control of the camera enabling the surgeon to focus on other critical surgical tasks.

The Company is announcing incremental features sets which are now under development:

- An Analytical Feature Set, which includes pre-operative surgical planning that will allow surgeons to map out and plan for specific surgical actions intraoperatively using the ISU's Augmented Intelligence
- A Safety Feature Set, which includes "no fly zone" functionality that will enable the identification and marking of potential hazards during the operation, thereby restricting instruments from entering into defined anatomical structures
- A Training and Education Set, which includes telestration, allowing multiple team members to work together in real-time by annotating, highlighting and drawing on a shared visual display of the surgical field

Cloud Data Architecture and Machine Learning

Asensus Surgical previously announced that it agreed on a multi-year strategic collaboration with Google Cloud to integrate Google Cloud's secure cloud data architecture and machine learning technologies to further expand the capabilities of the Asensus Surgical's Performance-Guided Surgery framework enabled through the ISU. Google's secure cloud data architecture will capture this data and Asensus will enable customer access portals and performance dashboards for surgeons and hospitals. Google's machine learning technologies will be utilized to analyze the data and discern clinical intelligence that can be utilized by surgeons and hospitals in addition to continuously improving the software in the ISU to provide better intra-operative clinical insight. This collaboration to better capture clinical performance data and apply Augmented Intelligence capabilities is expected to provide clinical insight and drive superior outcomes for patients.

KARL STORZ Collaboration Agreement

The Company previously announced that it had entered into a Memorandum of Understanding with KARL STORZ VentureONE Pte. Ltd. (KARL STORZ), a new wholly owned subsidiary of KARL STORZ SE & Co. KG, a global leader in the medical technologies industry, especially in the area of endoscopes, medical instruments, and devices that offers state-of-the-art technology for minimally invasive procedures in virtually all surgical specialties. As part of this agreement, KARL STORZ intends to market and sell Asensus' Intelligent Surgical Unit as a standalone device together with their IMAGE1 S™ Imaging system and OR1™ integration solution. The companies also intend to work together on the integration of the ISU into KARL STORZ's laparoscopic vision systems and jointly collaborate on developing next-generation instrumentation to be used with Asensus and KARL STORZ surgical platforms. As a solution-oriented and innovative partner, KARL STORZ is in close collaboration with surgeons and health care partners around the globe to enable them to perform at their very best every day to improve patients' lives. Upon finalization of the definitive agreements, the ISU's will bring its advanced Augmented Intelligence capabilities to operating rooms around the world.

February 2023 Investor Day

The Company is hosting an Investor Day today, Tuesday, February 21, 2023 in New York, NY. The event will begin at 11:30 AM EST. A live webcast of the conference presentation will be available online on the investor relations page of the Company's website at https://ir.asensus.com/events-and-presentations. Replays of the webcasts will be archived on the website.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. Based upon the foundation of Digital Laparoscopy with the Senhance Surgical System, the Company is developing the LUNA Surgical System, a next generation robotic and instrument system as a foundation of its Digital Surgery solution. These systems will be powered by the Intelligent Surgical Unit to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Senhance Surgical System is now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. To learn more about Performance-Guided Surgery, Digital Laparoscopy with the Senhance Surgical System and the new LUNA System visit www.asensus.com.

Follow Asensus

Email Alerts: https://ir.asensus.com/email-alerts

LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc

Twitter: https://twitter.com/AsensusSurgical

YouTube: https://www.youtube.com/c/transenterix

Vimeo: https://vimeo.com/asxc

Forward-Looking Statements

This press release includes statements relating to Asensus Surgical and its corporate update. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether Asensus Surgical will be able to successfully develop its LUNA Surgical System, whether Asensus Surgical's Digital solution will enable its vision of Performance-Guided Surgery, whether the LUNA Surgical System will revolutionize the way surgery is performed, whether the incremental features sets under development for the ISU will be successful, whether the collaboration between Asensus Surgical and Google Cloud will be successful and whether definitive agreements will be successfully negotiated and lead to a successful collaboration between Asensus Surgical and Karl Storz. For a discussion of the risks and uncertainties associated with the Company's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:

Mark Klausner or Mike Vallie, 443-213-0499

invest@asensus.com

MEDIA CONTACT:

Isabella Rodriguez, 708-833-1572

CG Life

irodriguez@cglife.com